- Home
- ACRE vs KROS Comparison
ACRE vs KROS Comparison
Compare ACRE & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | KROS |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.4M | 206.0M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACRE | KROS |
|---|---|---|
| Price | $4.88 | $11.10 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $5.38 | ★ $21.86 |
| AVG Volume (30 Days) | ★ 512.9K | 189.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 11.58% | N/A |
| EPS Growth | 26.17 | ★ 146.00 |
| EPS | ★ 1.35 | N/A |
| Revenue | $54,833,000.00 | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.28 | $2,751.79 |
| P/E Ratio | $3.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.14 | $9.69 |
| 52 Week High | $5.89 | $22.55 |
Technical Indicators
Market Signals| Indicator | ACRE | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 52.70 |
| Support Level | $4.67 | $10.57 |
| Resistance Level | $5.06 | $11.55 |
| Average True Range (ATR) | 0.14 | 0.45 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 81.43 | 75.00 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.